These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 22825407

  • 1. Intravitreal bevacizumab treatment for exudative age-related macular degeneration with good visual acuity.
    Axer-Siegel R, Bor E, Bourla DH, Weinberger D, Mimouni K.
    Retina; 2012 Oct; 32(9):1811-20. PubMed ID: 22825407
    [Abstract] [Full Text] [Related]

  • 2. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity.
    Saito M, Iida T, Kano M.
    Retina; 2012 Jul; 32(7):1250-9. PubMed ID: 22446886
    [Abstract] [Full Text] [Related]

  • 3. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
    Dunavoelgyi R, Sacu S, Eibenberger K, Palkovits S, Leydolt C, Pruente C, Schmidt-Erfurth U.
    Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections.
    Mekjavic PJ, Kraut A, Urbancic M, Lenassi E, Hawlina M.
    Acta Ophthalmol; 2011 Nov; 89(7):647-53. PubMed ID: 19860774
    [Abstract] [Full Text] [Related]

  • 5. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
    Sonmez K, Sonmez PA, Ozkan SS, Atmaca LS.
    Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
    [Abstract] [Full Text] [Related]

  • 6. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR, Mahajan VB.
    Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
    [Abstract] [Full Text] [Related]

  • 7. Bevacizumab for neovascular age-related macular degeneration in China.
    Li X, Hu Y, Sun X, Zhang J, Zhang M, Neovascular Age-Related Macular Degeneration Treatment Trial Using Bevacizumab (NATTB).
    Ophthalmology; 2012 Oct; 119(10):2087-93. PubMed ID: 22818896
    [Abstract] [Full Text] [Related]

  • 8. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
    Bidot ML, Malvitte L, Bidot S, Bron A, Creuzot-Garcher C.
    J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration.
    Yoganathan P, Deramo VA, Lai JC, Tibrewala RK, Fastenberg DM.
    Retina; 2006 Jun; 26(9):994-8. PubMed ID: 17151485
    [Abstract] [Full Text] [Related]

  • 11. Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes.
    Baek JS, Cho HJ, Cho SW, Kim CG, Kim JW.
    Retina; 2013 Mar; 33(3):467-73. PubMed ID: 23400082
    [Abstract] [Full Text] [Related]

  • 12. Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage.
    Treumer F, Roider J, Hillenkamp J.
    Br J Ophthalmol; 2012 May; 96(5):708-13. PubMed ID: 22174095
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Effectivity and safety of bevacizumab intravitreal injections for exudative age-related macular degeneration treatment--6 months observations].
    Małgorzata F.
    Klin Oczna; 2010 May; 112(7-9):213-6. PubMed ID: 21121123
    [Abstract] [Full Text] [Related]

  • 15. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF, Fromow-Guerra J, Sanchez JG, Maia M, Berrocal MH, Wu L, Saravia MJ, Costa RA, Pan-American Collaborative Retina Study Group.
    Retina; 2008 May; 28(10):1387-94. PubMed ID: 18827735
    [Abstract] [Full Text] [Related]

  • 16. Fixed-interval versus OCT-guided variable dosing of intravitreal bevacizumab in the management of neovascular age-related macular degeneration: a 12-month randomized prospective study.
    El-Mollayess GM, Mahfoud Z, Schakal AR, Salti HI, Jaafar D, Bashshur ZF.
    Am J Ophthalmol; 2012 Mar; 153(3):481-489.e1. PubMed ID: 22014603
    [Abstract] [Full Text] [Related]

  • 17. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab.
    Cho H, Shah CP, Weber M, Heier JS.
    Br J Ophthalmol; 2013 Aug; 97(8):1032-5. PubMed ID: 23766432
    [Abstract] [Full Text] [Related]

  • 18. Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of injections every 4 weeks, 6 weeks and 8 weeks.
    Lushchyk T, Amarakoon S, Martinez-Ciriano JP, van den Born LI, Baarsma GS, Missotten T.
    Acta Ophthalmol; 2013 Sep; 91(6):e456-61. PubMed ID: 23773796
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
    Dadgostar H, Ventura AA, Chung JY, Sharma S, Kaiser PK.
    Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
    [Abstract] [Full Text] [Related]

  • 20. Causes of unsuccessful ranibizumab treatment in exudative age-related macular degeneration in clinical settings.
    Cohen SY, Oubraham H, Uzzan J, Dubois L, Tadayoni R.
    Retina; 2012 Sep; 32(8):1480-5. PubMed ID: 22258164
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.